Reports Q4 revenue $16.7M, consensus $15.4M. "We are excited to have completed our strategic review of the business, which has resulted in a new threefold focus on winning in MRD, leveraging our technology to power companies working on personalized cancer vaccines, and supporting pharmaceutical customers with clinical trials," said Aaron Tachibana, Interim Chief Executive Officer and Chief Financial Officer. "Our partnership with Moderna using our NeXT Platform to provide genomic testing is an example of how we enable customers. With our sharpened focus in both our clinical and biopharma businesses, we believe we are well-positioned to advance the standard of care by transforming cancer recurrence detection and ongoing therapy monitoring."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PSNL:
- Personalis upgraded to Buy at Needham on cost reductions, biopharma potential
- Personalis upgraded to Buy from Hold at Needham
- Personalis, Moderna announce new agreement to leverage NeXT Platform
- Personalis raises FY22 revenue view to about $65M, consensus $63.6M
- Personalis sees Q4 revenue approximately $16.7M, consensus $15.33M
